Researchers assessed latest apps that claim to help diagnose questionable moles as melanoma. The performance of the apps is highlight variable- 3 of 4 apps incorrectly classified one-third of melanomas as “not concerning”.
- clinical trial
Researchers at the Dana-Farber and Broad Institute in Boston identified 2 mutations that collectively occur in 71 percent of malignant melanoma tumors making them more common than the BRAF mutation. These highly “recurrent” mutations may be the most common mutations in melanoma cells found to date. The mutations are located in non-protein-coding DNA that regulates the activity of genes, both located in the promoter region of TERT, the telomerase enzyme
Still in the pre-clinical stages, IL-17E immunotherapy is slated to enter clincial tirals as monotherapy and combo therapy for cancers including melanoma, pancreatic, gastric, colon, ovarian, breast, and lung cancers.
Melanoma researchers from the U.S. and Australia highlight that the recent success of targeted agents and immunotherapies for treatment of melanoma should be tested in combination clinical trials, particularly in the adjuvant setting
Retrospective analysis of 520 melanoma patients with a negative sentinel lymph node biopsy showed an overall recurrence rate of 16%, with median follow-up of 61 months. For recurrences in the sampled nodal basin, the false-negative rate was 4%. Age, Breslow thickness, ulceration, and head and neck lesions significantly predicted recurrence.
Pharmaceutical giant GlaxoSmithKline (NYSE: GSK ) announced in a press release that it has begun a phase 3 study to find out whether two of its drugs — its BRAF inhibitor dabrafenid and MEK inhibitor trametinib — can combine to work as a successful therapy for melanoma.
Review of the available data to best guide initial treatment choice and the sequence of treatments for patients with BRAF Val600 mutant melanoma.
Study finds phosphorylation of Mps1 by BRAFV600E prevents Mps1 degradation and contributes to chromosome instability in melanoma. The results raise the possibility that targeting the oncogenic BRAF and S281-phosphorylated Mps1, especially when used in combination could potentially provide great therapeutic opportunities for cancer treatment.
Phase III trial of treatment-naive metastatic melanoma comparing tremelimumab with physician’s choice standard-of-care chemotherapy failed to show an improved overall survival for the immunotherapy antibody.